Holen Sie sich die Stockscreener-App
2.36
1.72%
0.04
Handel nachbörslich:
2.31
-0.05
-2.12%
Schlusskurs vom Vortag:
$2.32
Offen:
$2.32
24-Stunden-Volumen:
431.13K
Relative Volume:
0.58
Marktkapitalisierung:
$168.25M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-104.08M
KGV:
-1.6774
EPS:
-1.4069
Netto-Cashflow:
$-89.91M
1W Leistung:
+18.00%
1M Leistung:
-5.60%
6M Leistung:
+9.77%
1J Leistung:
+44.79%
1-Tages-Spanne:
$2.3101
$2.425
1-Wochen-Bereich:
$2.04
$2.425
52-Wochen-Spanne:
$1.42
$2.81
Nkarta Inc Stock (NKTX) Company Profile
Firmenname
Nkarta Inc
Sektor
Branche
Telefon
(925) 407-1049
Adresse
1150 VETERANS BOULEVARD, SOUTH SAN FRANCISCO
Compare NKTX vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NKTX
Nkarta Inc
|
2.36 | 165.39M | 0 | -104.08M | -89.91M | -1.4069 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Nkarta Inc Stock (NKTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-15 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2024-10-09 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-08-14 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-03-22 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2022-12-22 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-10-10 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-07-28 | Eingeleitet | Needham | Buy |
| 2022-07-18 | Eingeleitet | SVB Leerink | Outperform |
| 2022-03-11 | Eingeleitet | Raymond James | Outperform |
| 2022-03-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-01-06 | Eingeleitet | William Blair | Outperform |
| 2021-11-18 | Eingeleitet | SMBC Nikko | Outperform |
| 2021-07-16 | Eingeleitet | Oppenheimer | Outperform |
| 2020-08-04 | Eingeleitet | Cowen | Outperform |
| 2020-08-04 | Eingeleitet | Evercore ISI | Outperform |
| 2020-08-04 | Eingeleitet | Mizuho | Buy |
| 2020-08-04 | Eingeleitet | Stifel | Buy |
Alle ansehen
Nkarta Inc Aktie (NKTX) Neueste Nachrichten
Idiopathic Membranous Nephropathy Market is Predicted to Reach USD 1 Billion by 2036 Due to Rising Therapeutic Options | DelveInsight - GlobeNewswire Inc.
Nkarta, Inc. (NASDAQ:NKTX) Given Average Recommendation of "Hold" by Analysts - MarketBeat
[EFFECT] Nkarta, Inc. SEC Filing - Stock Titan
If You Invested $1,000 in Nkarta, Inc. (NKTX) - Stock Titan
Nkarta (NASDAQ: NKTX) launches $100M ATM shelf via Stifel as sales agent - Stock Titan
NKTX Technical Analysis & Stock Price Forecast - Intellectia AI
Nkarta (NASDAQ:NKTX) Price Target Lowered to $12.00 at Mizuho - Defense World
NKTX PE Ratio & Valuation, Is NKTX Overvalued - Intellectia AI
Mizuho lowers Nkarta stock price target on sales ramp moderation - investing.com
HC Wainwright Forecasts Nkarta’s Q1 Earnings (NASDAQ:NKTX) - Defense World
HC Wainwright Forecasts Nkarta's Q1 Earnings (NASDAQ:NKTX) - MarketBeat
Nkarta (NASDAQ:NKTX) Rating Lowered to Sell at Wall Street Zen - MarketBeat
TD Cowen Maintains Nkarta(NKTX.US) With Buy Rating - Moomoo
Risk Hedge: Will Nkarta Inc stock go up in YEARPortfolio Performance Summary & Daily Stock Trend Watchlist - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: Nkarta (NKTX), QT Imaging Holdings (QTI) and Cardiff Oncology (CRDF) - The Globe and Mail
Nkarta Launches $100 Million At-the-Market Stock Offering - The Globe and Mail
Nkarta (NASDAQ:NKTX) Price Target Raised to $11.00 at Needham & Company LLC - Defense World
Nkarta, Inc. Files Form 8-K With SEC Detailing Company and Stock Information – March 25, 2026 - Minichart
NKTX (Nkarta) PB Ratio : 0.51 (As of Mar. 26, 2026) - GuruFocus
Nkarta (NASDAQ:NKTX) Stock Price Expected to Rise, Needham & Company LLC Analyst Says - MarketBeat
Stifel reiterates Nkarta stock rating on trial enrollment progress By Investing.com - Investing.com South Africa
Stifel reiterates Nkarta stock rating on trial enrollment progress - Investing.com
Nkarta launches $100M at-the-market equity program with Stifel - TradingView
Nkarta, Inc. 2025 Annual Report: Advancing Allogeneic CAR NK-Cell Therapies for Cancer and Autoimmune Diseases - Minichart
Nkarta Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Aug Momentum: Should value investors consider Nkarta Inc2026 Institutional & Real-Time Volume Triggers - baoquankhu1.vn
Nkarta, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Nkarta (NASDAQ: NKTX) launches $100M at-the-market stock sale plan - Stock Titan
Nkarta Files $350 Million Mixed Shelf - marketscreener.com
Nkarta (NASDAQ: NKTX) launches $100M at-the-market program via $350M shelf - Stock Titan
Nkarta (NASDAQ:NKTX) Releases Quarterly Earnings Results, Misses Expectations By $0.05 EPS - MarketBeat
Nkarta 2025 10-K: Net loss $104.1M, EPS $(1.41) - TradingView
[10-K] Nkarta, Inc. Files Annual Report - Stock Titan
Nkarta (NASDAQ: NKTX) reports 2025 loss and extends cash runway to 2029 - stocktitan.net
Nkarta reports fourth quarter and full year 2025 financial results and corporate highlights - MarketScreener
Nkarta Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights - globenewswire.com
Nkarta (NKTX) to Release Earnings on Tuesday - Defense World
Trend Report: Is Nkarta Inc stock a buy or sell2026 Levels & Reliable Intraday Trade Plans - baoquankhu1.vn
Nkarta Inc expected to post a loss of 32 cents a shareEarnings Preview - TradingView
NKTX Q4'25 Earnings: EPS estimate is (0.31) USD - tradingview.com
Trading Action: Will Nkarta Inc face regulatory challenges2026 Pullback Review & Weekly Setup with High ROI Potential - baoquankhu1.vn
Street Watch: Will Nkarta Inc stock go up in YEAR2026 Volatility Report & Fast Moving Stock Watchlists - baoquankhu1.vn
Nkarta, Inc. (NASDAQ:NKTX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Sectors Review: Is Nkarta Inc stock showing strong momentumMarket Movers & Verified Swing Trading Watchlists - baoquankhu1.vn
Aug Big Picture: How do insiders feel about Nkarta Inc2026 Earnings Impact & High Return Trade Guides - baoquankhu1.vn
Risk On: How sensitive is Nkarta Inc to inflation2025 Earnings Impact & Capital Efficient Trade Techniques - baoquankhu1.vn
NKTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Nkarta to Participate in March Investor Conferences - Yahoo Finance
Profit Review: Does Nkarta Inc have declining or rising EPSWeekly Trade Summary & Reliable Momentum Entry Alerts - baoquankhu1.vn
NKTXNkarta, Inc. Latest Stock News & Market Updates - Stock Titan
Why analysts upgrade Nkarta Inc. stockJuly 2025 Fed Impact & Capital Protection Trade Alerts - mfd.ru
Finanzdaten der Nkarta Inc-Aktie (NKTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Nkarta Inc-Aktie (NKTX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Mahmood Nadir | President |
Jan 15 '26 |
Sale |
2.07 |
5,649 |
11,693 |
167,727 |
| HASTINGS PAUL J | Chief Executive Officer |
Jun 18 '25 |
Sale |
1.79 |
1,790 |
3,204 |
320,069 |
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):